Format

Send to

Choose Destination
Front Oncol. 2018 Apr 11;8:88. doi: 10.3389/fonc.2018.00088. eCollection 2018.

Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment.

Author information

1
Medical Oncology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
2
Cancer Medicine Department, Institut Gustave Roussy, Villejuif, France.
3
University Paris-Sud, Orsay, France.

Abstract

Brain metastases (BM) are common in non-small cell lung cancer patients including in molecularly selected populations, such as EGFR-mutant and ALK-rearranged tumors. They are associated with a reduced quality of life, and are commonly the first site of progression for patients receiving tyrosine kinase inhibitors (TKIs). In this review, we summarize incidence of BM and intracranial efficacy with TKI agents according to oncogene driver mutations, focusing on important clinical issues, notably optimal first-line treatment in oncogene-addicted lung tumors with upfront BM (local therapies followed by TKI vs. TKI monotherapy). We also discuss the potential role of newly emerging late-generation TKIs as new standard treatment in oncogene-addicted lung cancer tumors compared with sequential strategies.

KEYWORDS:

ALK; EGFR; brain; metastases; non-small cell lung cancer

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center